Observational studyBMJ open2019
Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care.
Observational study in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07759752 (Transurethral Thermodilatation Versus Prostatic Urethral Lift for Moderate-to-Severe BPH), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transurethral Thermodilatation Versus Prostatic Urethral Lift for Moderate-to-Severe BPH: A Randomised Controlled Non-Inferiority Trial
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Self-Management for Men With Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis.Annals of family medicinePooled it
- Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Randomized trial of unilateral versus bilateral percutaneous tibial nerve stimulation for the treatment of overactive bladder.World journal of urology · 2025Trial
- Evaluating the impact of digital therapy for male LUTS: insights from the BEST trial subgroup analysis.World journal of urology · 2025Trial
- Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.BJU international · 2025Trial
- Transvaginal Electrical Stimulation for Treatment of Overactive Bladder Without Incontinence: A Pilot Cross-Over Clinical Trial.Neurourology and urodynamics · 2025Trial
- Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: A GRADE-Assessed Systematic Review and Meta-Analysis.Cardiovascular and interventional radiology · 2026Article
- Responsiveness, Minimal Detectable Change, and Minimal Clinically Important Difference of the Turkish Version of the 8-item Overactive Bladder Questionnaire.International urogynecology journal · 2026Article
- Efficacy of behavioral therapy and different dosages of mirabegron for the treatment of male overactive bladder patients.International urology and nephrology · 2026Article
- Defining the Minimal Important Difference in International Prostate Symptom Score for Men with Lower Urinary Tract Symptoms Using a Patient-centered Anchor Measure.European urology open science · 2025Article
- Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping Study: Methods and Baseline Urinary Symptoms by Age and Sex.Neurourology and urodynamics · 2025Article
- Article
- Outcomes of open vs laparoscopic vs robotic vs transanal total mesorectal excision (TME) for rectal cancer: a network meta-analysis.Techniques in coloproctology · 2023Review
- Semi-Automatic MRI Feature Assessment in Small- and Medium-Volume Benign Prostatic Hyperplasia after Prostatic Artery Embolization.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the minimal important difference (MID) of the International Prostate Symptom Score (IPSS) and the Overactive Bladder Questionnaire short form (OAB-q SF) assessed in primary care among patients treated for lower urinary tract symptoms (LUTS).
designSingle-arm, open-label observational cohort study with a 6-week follow-up.
settingTwenty-two pharmacies in the Netherlands.
participantsWe enrolled Dutch men with uncomplicated LUTS who received a new alpha-blocker prescription from their general practitioner or urologist. PRIMARY AND SECONDARY OUTCOMES: The IPSS and OAB-q SF were completed before and after 6 weeks of therapy. At 6 weeks, men also completed the Patient Global Impression of Improvement (PGI-I). The mean change scores of the IPSS and OAB-q SF were calculated for each PGI-I outcome category, with the category 'a little better' used to determine the MID. The SE of measurement (SEM) was calculated for each questionnaire.
resultsIn total, 165 men completed follow-up. The MID was 5.2 points (95% CI 3.9 to 6.4; SEM 3.6) for the IPSS and 11.0 points (95% CI 7.1 to 14.9; SEM 9.7) for the OAB-q SF. For both questionnaires, CIs showed an overlap with the no-change categories. However, the MID for the IPSS was higher in men with severe baseline symptoms (7.1; 95% CI 5.3 to 9.0) than in men with moderate baseline symptoms (3.2; 95% CI 1.7 to 4.8).
conclusionIn this study, the MID for the IPSS was considerably higher than the MID of 3.1 reported in the only other study on this topic, but may be due to methodological differences. Interpretation of the MID for the OAB-q SF is hampered by the overlap with the SEM. Future studies are needed to confirm our results because correlations between the PGI-I and symptom questionnaires were suboptimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.